EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in targeting p38 MAPK for cancer therapy: insights from molecular pharmacology and medicinal chemistry

Ritesh P Bhole, Nishigandha Kadam, Pawan N Karwa, Sonali D Labhade, Harshad S Kapare, Shailendra Gurav

Molecular Diversity · 21.07.2025 · 30 (5) · 6559-6587

DOI: 10.1007/s11030-025-11291-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Diversity, online erschienen am 21.07.2025. Verfasst von Ritesh P Bhole und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, India. ritesh.bhole@dypvp.edu.in. Hauptthemen laut MEDLINE: p38 Mitogen-Activated Protein Kinases, Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 152 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The p38 mitogen-activated protein kinase (MAPK) pathway plays a pivotal role in inflammatory responses, cell proliferation, differentiation, and cancer progression. Among its four isoforms (p38α, p38β, p38γ, and p38δ), p38α is the most widely studied and has been implicated in various malignancies, making it a compelling target for therapeutic intervention. This review systematically explores recent developments in both synthetic and natural small-molecule inhibitors of p38 MAPK with a focus on their relevance in cancer treatment. Two major classes of p38 inhibitors are highlighted: ATP-competitive inhibitors that block the kinase by targeting the ATP-binding pocket (e.g., SB203580, Ralimetinib), and allosteric inhibitors that interact with regulatory regions outside the active site, inducing conformational changes to suppress kinase activity (e.g., BIRB796). The manuscript further categorizes inhibitors based on chemical scaffolds and source, discusses structure-activity relationships (SAR), and outlines their mechanistic impact on the p38 MAPK signaling axis in various cancers. This review also emphasizes the therapeutic challenges, subtype selectivity, and opportunities for isoform-specific drug design. Ultimately, a comprehensive understanding of these mechanisms can support the rational development of p38 MAPK inhibitors with improved efficacy and selectivity in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p38 Mitogen-Activated Protein KinasesNeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsMolecular Targeted TherapyHumansAnimalsChemistry, PharmaceuticalStructure-Activity Relationship

Stichwörter der Autor:innen

Cancer therapyDrug developmentKinase inhibitorsMAPK signalingSmall-molecule inhibitorsp38 MAPK

Substanzen

p38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, India. ritesh.bhole@dypvp.edu.in.
  • Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India. ritesh.bhole@dypvp.edu.in.
  • Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, India.
  • School of Pharmacy and Research, Dr. D. Y. Patil Dnyan Prasad University, Pimpri, Pune, India.
  • Department of Pharmacognosy, Goa College of Pharmacy, Goa, India.

Zitieren

APA

Bhole, R. P., Kadam, N., Karwa, P. N., Labhade, S. D., Kapare, H. S., & Gurav, S. (2025). Advances in targeting p38 MAPK for cancer therapy: insights from molecular pharmacology and medicinal chemistry. Molecular Diversity, 30(5), 6559-6587. https://doi.org/10.1007/s11030-025-11291-7

Vancouver

Bhole RP, Kadam N, Karwa PN, Labhade SD, Kapare HS, Gurav S. Advances in targeting p38 MAPK for cancer therapy: insights from molecular pharmacology and medicinal chemistry. Molecular Diversity. 2025;30(5):6559-6587. doi:10.1007/s11030-025-11291-7

BibTeX
@article{Bhole2025,
  author = {Bhole, Ritesh P and Kadam, Nishigandha and Karwa, Pawan N and Labhade, Sonali D and Kapare, Harshad S and Gurav, Shailendra},
  title = {Advances in targeting p38 MAPK for cancer therapy: insights from molecular pharmacology and medicinal chemistry},
  journal = {Molecular Diversity},
  year = {2025},
  volume = {30},
  number = {5},
  pages = {6559--6587},
  doi = {10.1007/s11030-025-11291-7}
}
Kostenlos starten →